Neisvac-C

N. meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid, the active ingredient in Neisvac-C, is a vaccine presented as an injectable solution for intramuscular use. It is used to prevent invasive disease caused by Neisseria meningitidis serogroup C in individuals at risk.

GNH USA supplies Neisvac-C as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neisvac-C is a meningococcal conjugate vaccine indicated for prevention of invasive disease caused by Neisseria meningitidis serogroup C. - Infants and toddlers: induction of protective antibodies against serogroup C meningococcal disease. - Adolescents and young adults: maintenance of immunity to prevent invasive meningococcal C infection. - Adults at increased risk (e.g., travelers, immunocompromised): reduction of incidence of serogroup C invasive disease.

Neisvac-C is generally well tolerated, but injection‑site reactions and systemic symptoms may occur.

Common Side Effects: - Pain at the injection site: mild to moderate discomfort. - Redness or swelling: localized inflammatory response. - Fever: transient low‑grade temperature rise. - Headache: mild to moderate intensity. - Fatigue: temporary tiredness. - Myalgia: muscle aches near the injection area.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare autoimmune neuropathy. - Seizures: uncommon neurologic event. - Hypotension: sudden drop in blood pressure. - Severe local necrosis: extensive tissue damage at injection site. - Thrombotic events: extremely rare clot formation.

Before administering Neisvac-C, consider the following safety measures. - Pregnancy: safety not established; use only if benefits outweigh risks. - Breastfeeding: unknown effects; evaluate risk‑benefit ratio. - Immunocompromised patients: may mount a reduced immune response. - Severe allergy: avoid if known hypersensitivity to any vaccine component. - Concomitant vaccines: follow recommended intervals to avoid interference. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neisvac-C may interact with other agents; monitor as indicated.

Major Interactions (Avoid): - Live attenuated vaccines: avoid simultaneous administration to prevent interference. - Whole‑blood transfusion: postpone vaccination for at least 4 weeks after transfusion.

Moderate Interactions (Monitor Closely): - Immunoglobulin therapy: may diminish vaccine‑induced immunity; schedule vaccination before therapy when possible. - Antipyretics (e.g., acetaminophen): can mask fever, monitor for underlying infection. - Immunosuppressive drugs: may reduce antibody response; assess need for booster doses. - Antibiotics: generally no effect, but monitor for allergic cross‑reactivity if penicillin‑based.